Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales
Rhea-AI Summary
Visionary Holdings (NASDAQ: GV) provided a 2026–2027 business outlook, emphasizing a strategic shift into higher‑margin healthcare services and medical aesthetics. Management said commercialization of the RAMU anti‑aging product line could potentially reach approximately US$30 million in annual sales, subject to market conditions, regulatory approvals, and execution.
The company plans continued expansion into North America and Europe via product commercialization, distribution partnerships, and healthcare service collaborations, and intends to develop an integrated healthcare services platform combining products, wellness services, and biotechnology.
Positive
- RAMU sales target approximately US$30 million annually (2026–2027)
- Strategic shift toward higher‑margin healthcare and medical aesthetics
- Planned expansion into North America and Europe via partnerships
Negative
- RAMU sales projection subject to regulatory approvals and execution
- International commercialization depends on market conditions and distribution success
News Market Reaction – GV
On the day this news was published, GV declined 2.38%, reflecting a moderate negative market reaction. This price movement removed approximately $111K from the company's valuation, bringing the market cap to $5M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GV is up 1.36% while peers show mixed moves: AMBO up 1.31%, KIDZ up 10.46%, EEIQ and FEDU down, and WAFU flat. This pattern points to stock-specific dynamics rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Distribution agreement | Positive | -5.1% | Exclusive Huajin China deal with <b>US$12M</b> minimum sales and divestiture of education. |
| Feb 24 | Sales contract update | Positive | -9.3% | Update on execution of approximately <b>US$9M</b> commercial sales agreement. |
| Feb 18 | China expansion | Positive | -1.8% | Creation of three wholly owned subsidiaries to support regenerative and aesthetic products. |
| Feb 13 | Convertible financing | Positive | -0.9% | Issuance of <b>$500,000</b> senior secured convertible note for <b>$450,000</b> proceeds. |
| Feb 04 | Nasdaq compliance | Positive | -2.5% | Resolution of Nasdaq filing deficiency and confirmation of continued listing. |
Recent positive operational and financing updates have repeatedly been followed by negative 24-hour price reactions, indicating a pattern of selling into news.
Over the last month, GV reported several business-building steps, including a US$12 million exclusive distribution deal, progress on an approximately US$9 million sales contract, and new subsidiaries in three Chinese cities. It also raised $450,000 via a convertible note and resolved a Nasdaq filing deficiency. Despite generally constructive headlines, shares fell after each event, framing today’s 2026–2027 growth outlook against a backdrop of skeptical price responses.
Market Pulse Summary
This announcement outlines Visionary’s 2026–2027 focus on higher-margin medical aesthetics and the RAMU anti-aging line, which management believes could reach US$30 million in annual sales. Set against a prior 50% revenue decline and ongoing tax and financing obligations, the outlook highlights both opportunity and risk. Investors may watch actual RAMU commercialization progress, execution of existing US$9–12 million contracts, and any further balance-sheet developments.
Key Terms
medical aesthetics medical
regenerative healthcare medical
anti-aging medical
AI-generated analysis. Not financial advice.
Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy
HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets.
Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding into international healthcare markets, including North America and Europe, through product commercialization, healthcare service collaborations, and international distribution partnerships.
Management believes that the global medical aesthetics and anti-aging industry continues to demonstrate strong long-term growth potential, driven by increasing consumer demand for advanced aesthetic treatments and regenerative healthcare solutions.
2026–2027 Business Outlook
Management believes that the period from 2026 through 2027 may represent an important stage in the Company’s commercialization and international expansion within the healthcare and medical aesthetics sectors.
Visionary expects that the commercialization of its RAMU anti-aging product line, part of the Company’s medical aesthetics and regenerative healthcare portfolio, may become an important driver of revenue growth during this period.
Based on current market expansion plans and distribution arrangements, management believes that RAMU-related product sales could potentially reach approximately US
The Company also expects that these business segments may deliver relatively higher gross margins compared with certain legacy businesses, reflecting the premium positioning of medical aesthetics and anti-aging products within the global healthcare and wellness market.
Revenue recognition and financial results will be determined in accordance with applicable accounting standards and the Company’s financial reporting cycles.
Strategic Growth Priorities
Expansion into International Medical Aesthetics Markets
Building on previously announced initiatives, the Company plans to continue expanding its presence in international healthcare markets, including North America and Europe, through product commercialization, distribution partnerships, and healthcare service collaborations.
Commercialization of Anti-Aging Products
Visionary intends to accelerate the commercialization of its RAMU anti-aging product line, targeting premium medical aesthetics and regenerative healthcare applications.
Development of Integrated Healthcare Services Platform
The Company plans to further develop healthcare service platforms that combine medical aesthetics products, wellness services, and advanced biotechnology applications.
Management Commentary
Mr. Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:
“Visionary has been actively advancing its strategic transition toward healthcare services and medical aesthetics. We believe the period from 2026 to 2027 represents an important stage for the commercialization of our products and the expansion of our international healthcare initiatives.
Our strategy focuses on combining product commercialization, healthcare services, and international partnerships. We believe that the RAMU anti-aging product line, together with our expanding healthcare service network, may create meaningful growth opportunities for Visionary in the global medical aesthetics and wellness markets.”
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Contacts:
Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings
FAQ
What sales does Visionary (GV) project for RAMU in 2026–2027?
How is Visionary (GV) changing its strategic focus for 2026–2027?
Where will Visionary (GV) expand its medical aesthetics business?
What risks did Visionary (GV) highlight for RAMU commercialization?
Will Visionary (GV) change its product mix with the RAMU launch?
How does Visionary (GV) plan to support international commercialization of RAMU?
